Uniqure NV（QURE）の株式分析QUREUniqure NV

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $22.43, the stock is experiencing significant volatility and uncertainty following a 37% drop due to disappointing clinical trial results. The RSI is at 39.547, indicating the stock is nearing oversold territory, but the forward P/E ratio of 27.933 suggests high expectations for future earnings that may not be met. The main risk is the ongoing uncertainty around the FDA approval process for AMT-130, which could impact future performance.

5 analysts cover QURE: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 49.88.